Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease

Andreoli, . et al. (1997): Cecil Essentials of Medicine; (4-th ed.)- Company,.
Fauci, . et al. (1998): Harrison’s principles of internal medicine; (14-th ed.)-The McGraw-Hill Companies INC.,.
Shiau, ., Toren, . (2006): The Toronto Notes 2006: Comprehensive Medical References, 26-nd Ed., Canada.
Tierney, . (1997): Pocket guide to the essentials of diagnosis and treatment; (1-th ed.)- Lange medical book, .
Younger-Lewis,C.; Complete home medical guide;Canadian Medical Association (1-st ed.), Dk Publishing Inc.

Stopping corticosteroid therapy
In autoimmune disease, clear end-points should be set before starting therapy. Corticosteroids may improve mood and give patients a feeling of general well-being unrelated to the effect on the disease being treated. Subjective assessments can therefore be misleading. Objective clinical parameters should be used to monitor the need for continuing or restarting therapy . proteinuria in nephritis, spirometry in asthma and creatinine kinase in myositis. Therapy should be tapered off. For example, with prednis(ol)one, the dose is reduced in steps of -5 mg every 3-7 days down to 15 mg/day. At that point, switch to alternate day therapy and reduce in mg steps over 2-3 weeks. This minimises the impact on mood and lessens the drop in general well-being.

Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease

systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease

Media:

systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseasesystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseasesystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseasesystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary diseasesystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease